Validated MDA-MB-453 Xenograft Model:

Subcutaneous, Orthotopic, And Metastatic Xenograft Tumor Model

By Altogen Labs, 11200 Menchaca Road, Suite 203, Austin, TX 78748
Phone: (512) 433-6177 | Email: info@altogenlabs.com

Breast Cancer Research and the Role of Xenograft Models

Breast cancer remains one of the most prevalent and complex malignancies worldwide, exhibiting diverse molecular subtypes that influence prognosis and treatment strategies. While advancements in targeted therapies and immunotherapy have improved patient outcomes, preclinical research remains essential for developing and evaluating novel treatments. Xenograft models, particularly Cell Line Derived Xenografts (CDX) and Patient-Derived Xenografts (PDX), serve as critical tools in breast cancer research by providing *in vivo* systems that closely mimic human tumor biology. These models allow for the investigation of tumor growth dynamics, response to therapeutic agents, and mechanisms of drug resistance. CDX models, established from well-characterized cancer cell lines, offer reproducibility, whereas PDX models preserve the genetic and histopathological characteristics of patient tumors, making them valuable for personalized medicine research. By utilizing xenografts, researchers can assess the efficacy of chemotherapeutics, targeted therapies, and combination regimens under controlled conditions.

MDA-MB-453 Cell Line

The MDA-MB-453 cell line is a well-established human breast cancer cell line derived from a 48-year-old Caucasian female with metastatic breast carcinoma. Isolated in 1976 from a pericardial effusion, MDA-MB-453 cells exhibit characteristics typical of invasive ductal carcinoma and serve as an important model for the study of breast cancer biology. These cells are estrogen receptor-negative (ER-), progesterone receptor-negative (PR-), and HER2-positive, making them particularly useful for evaluating therapies targeting HER2 overexpression, such as trastuzumab. Additionally, MDA-MB-453 cells demonstrate a high degree of tumorigenic potential *in vivo*, often used in xenograft models to assess drug efficacy in metastatic breast cancer. The cell line is also known for its aggressive growth and propensity for developing resistance to chemotherapy over time. Researchers often utilize MDA-MB-453 to study the molecular mechanisms underlying breast cancer metastasis, chemoresistance, and the tumor microenvironment. As a valuable resource for preclinical drug development, this cell line continues to provide insights into targeted therapies and the progression of HER2-positive breast cancer.



Figure 1. Tumor Histology. H&E stained section of a subcutaneously-implanted MDA-MB-453 tumor (Altogen Labs).

Altogen Labs Validated MDA-MB-453 Xenograft Model

The study design involves the use of MDA-MB-453 cells, which are trypsinized, and their total viability is determined through the trypan blue assay, with a minimum required viability of 98%. The cell suspension is adjusted to a concentration of one million cells per 100 µL, mixed with Matrigel and subsequently injected subcutaneously into the flank of athymic BALB/C or NOD/SCID mice aged 10 to 12 weeks. Tumor establishment is monitored through visual observation and palpation. Once tumors are established, they are measured regularly with calipers until their average volume reaches 90-150 mm^3. Mice are then randomized into treatment groups as per the client's specifications, with daily tumor measurements and weight logs (taken three times a week) recorded throughout the study.



Figure 2. MDA-MB-453 breast cancer xenografted in immunocompromised mice, mean values +/- SEM (Altogen Labs).

Xenograft models are essential for evaluating the efficacy of novel therapeutic agents against specific cancer types. These models involve the inoculation of tumor cell lines into immunocompromised mice or rats, either subcutaneously or orthotopically, to monitor tumor growth and assess drug response. Standard preclinical testing of clinically approved anti-cancer agents has relied on such *in vivo* models. Xenograft studies require careful planning and execution, including the selection of the appropriate animal model, tumorigenic cell line, dosing regimen, and thorough analysis of tumor growth, including histological examination and mRNA and protein expression profiling. Additionally, the accurate assessment of tumor microenvironment interactions and their impact on drug efficacy is crucial for translating preclinical findings into successful clinical outcomes.



Figure 3. Tumor weight of MDA-MB-453 cells in control, buffer only mice and lapatinib treated mice at end of the study (Altogen Labs).

Subcutaneous MDA-MB-453 Breast Cancer Xenograft Model

The subcutaneous MDA-MB-453 xenograft model is a widely used preclinical system for studying molecular apocrine breast cancer in a controlled and reproducible manner. In this model, MDA-MB-453 cells are implanted subcutaneously into immunocompromised mice, typically in the hind legs, allowing for easy tumor monitoring and measurement. Unlike orthotopic models, subcutaneous implantation provides a simplified tumor environment, facilitating high-throughput drug screening and longitudinal studies. Tumor growth in this model is influenced by androgen receptor signaling, making it particularly relevant for evaluating AR-targeted therapies. Studies have shown that MDA-MB-453 subcutaneous tumors exhibit moderate growth rates and a defined histopathological profile, making them useful for testing novel therapeutic agents. Additionally, this model allows for the assessment of tumor vascularization, drug penetration, and molecular biomarkers in response to treatment. While it does not fully recapitulate the breast tumor microenvironment, the subcutaneous model remains a valuable tool for screening therapeutic efficacy before advancing to more complex in vivo systems.

The Orthotopic MDA-MB-453 Breast Cancer Model

The orthotopic MDA-MB-453 xenograft model is a valuable tool for studying molecular apocrine breast cancer, a subtype characterized by androgen receptor positivity and the absence of estrogen and progesterone receptors. In this model, MDA-MB-453 cells are implanted into the mammary fat pad of immunocompromised mice, providing a tumor microenvironment that closely mimics human breast cancer. Orthotopic implantation allows for the evaluation of tumor growth kinetics, therapeutic responses, and tumor-stroma interactions under physiologically relevant conditions. Studies utilizing this model have demonstrated its utility in assessing the efficacy of targeted therapies, including androgen receptor inhibitors and lipid-based drug formulations. Unlike more aggressive triple-negative breast cancer models, MDA-MB-453 tumors tend to exhibit moderate growth rates and lower metastatic potential. However, they provide an excellent platform for investigating the role of androgen signaling and alternative oncogenic pathways in breast cancer progression. The model also enables non-invasive imaging techniques and longitudinal studies, offering insights into tumor evolution and treatment resistance.

Metastatic MDA-MB-453 Xenograft Model

The metastatic MDA-MB-453 xenograft model is used to study the dissemination and colonization patterns of molecular apocrine breast cancer cells. While MDA-MB-453 tumors exhibit lower metastatic potential compared to highly aggressive triple-negative breast cancer models, they have been shown to spread under specific experimental conditions. Metastasis can be induced through orthotopic implantation followed by spontaneous dissemination, or by direct injection into circulation via the tail vein or left ventricle to model hematogenous spread. Studies suggest that MDA-MB-453 cells preferentially colonize the lungs, though metastatic efficiency is lower than that of basal-like breast cancer cell lines. This model enables researchers to investigate the role of androgen receptor signaling, tumor dormancy, and microenvironmental factors in metastatic progression. Additionally, it serves as a platform for testing anti-metastatic therapies, including androgen receptor antagonists and MEK inhibitors.

Alternative Chemotherapies: Anti-Metastatic Potential of Black Rice Anthocyanins

MDA-MB-453 is a HER2-positive breast cancer cell line frequently used in research to study tumor progression and metastasis. One promising area of investigation involves anthocyanins, plant-derived compounds with anti-cancer properties. Recent findings suggest that black rice anthocyanins (BRACs) can inhibit tumor growth and reduce metastasis in MDA-MB-453 xenograft models. Oral administration of BRACs in mice led to a significant decrease in lung metastases, suggesting its potential as a natural therapeutic strategy. *In vitro* studies confirmed that BRACs suppressed cell migration, adhesion, motility, and invasion, key factors in cancer metastasis. These effects were linked to the downregulation of urokinase-type plasminogen activator (u-PA), an enzyme crucial for tumor cell invasion. Interestingly, MDA-MB-453 cells were more sensitive to BRACs than HER2-negative breast cancer cells, highlighting the specificity of anthocyanins against aggressive breast cancer subtypes. These findings support the role of MDA-MB-453 as a critical model for evaluating natural compounds in cancer therapy.

Key Oncogenic Features of MDA-MB-453 Breast Cancer Cells

The MDA-MB-453 breast cancer cell line is characterized by several oncogenic alterations that drive its aggressive phenotype. It exhibits a mutation in the K-RAS gene (Gly13Asp), leading to constitutive activation of the MAPK/ERK signaling pathway, which promotes rapid proliferation. The cell line also lacks the tumor suppressor p16INK4A due to a deletion at the 9p21 locus, resulting in deregulation of the cell cycle through a p16-/pRb-/cyclin D1+ phenotype. This alteration contributes to excessive growth rates, as indicated by a high S-phase fraction. Additionally, while MDA-MB-453 is classified as an androgen receptor (AR)-positive, estrogen receptor (ER)-negative model, it lacks EGFR and HER2 gene amplifications, distinguishing it from many apocrine carcinomas. Despite its molecular apocrine classification, key differences in oncogenic pathways compared to patient tumors raise concerns about its suitability as a universal model for apocrine breast cancer.

Case Study: MDA-MB-453 Xenografts Reveal the Therapeutic Promise of Acetyltanshinone IIA

A study conducted by Guerram M, *et al*., published by *Oncotarget* journal explores the anticancer potential of Acetyltanshinone IIA (ATA) in HER2-overexpressing breast cancer, with a focus on the MDA-MB-453 cell line. ATA, derived from tanshinone IIA, effectively inhibited the growth of MDA-MB-453 cells, inducing S-phase cell cycle arrest and apoptosis. Mechanistically, ATA downregulated HER2 and EGFR receptor tyrosine kinases, leading to the inhibition of downstream pro-survival signaling pathways. Additionally, ATA activated AMP-activated protein kinase (AMPK), suppressing lipid and protein biosynthesis, both essential for cancer cell proliferation. In a xenograft model using MDA-MB-453 tumors, intraperitoneal administration of ATA significantly reduced tumor size without toxic side effects. The study also demonstrated that ATA-induced oxidative and endoplasmic reticulum (ER) stress, contributing to cancer cell death. Furthermore, ATA inhibited angiogenesis and tumor cell migration, suggesting its potential role in preventing metastasis. Overall, these findings highlight MDA-MB-453 as a valuable model for studying ATA's anti-cancer mechanisms and support its potential as a therapeutic agent for HER2-positive breast cancer.

Additional Case Study: Androgen Receptor Mutation in MDA-MB-453 Cells Alters Breast Cancer Signaling

Another study by Moore NL, *et al*., published by *Endocrine-Related Cancer* journal investigates the role of the MDA-MB-453 breast cancer cell line as a model for molecular apocrine breast cancer, a subtype characterized by androgen receptor (AR) signaling. Researchers identified a mutation in the AR gene of MDA-MB-453 cells, a G-T transversion in exon 7, leading to a Q865H amino acid substitution in the ligand-binding domain. This mutation resulted in reduced sensitivity to androgens such as dihydrotestosterone (DHT) and the progestin medroxyprogesterone acetate (MPA), altering AR transactivation potential. Functional analyses revealed that DHT and MPA activated distinct transcriptional programs, with DHT-associated genes resembling estrogen-responsive transcripts and engaging the Wnt signaling pathway, which promotes cell proliferation. In contrast, MPA regulated genes involved in cell cycle control and apoptosis, which may explain its inhibitory effects on MDA-MB-453 proliferation. Molecular modeling and ligand binding studies demonstrated that the Q865H mutation affects AR structural stability and intramolecular interactions. The findings highlight the necessity of studying alternative models of molecular apocrine breast cancer to fully understand AR's role and assess its potential as a therapeutic target.

Organoid Models for High-Throughput Drug Screening and Cancer Therapy

Organoids represent a sophisticated, three-dimensional *in vitro* culture system derived directly from patient tumor samples. These models retain many of the critical characteristics of the original tumors, including genetic and phenotypic diversity, which are often lost in conventional two-dimensional (2D) cell cultures. Unlike traditional 2D cultures, which typically lack the complex tissue architecture found in vivo, organoids replicate the structural and functional complexities of the tumor microenvironment. This makes them an invaluable tool for personalized cancer research, as they can be efficiently propagated from primary patient-derived material. The ability to culture organoids from patient biopsies ensures that individual tumor heterogeneity is preserved, allowing for more accurate modeling of cancer behavior and therapeutic responses. In contrast to xenograft and allograft models, which offer insights into tumor-stroma and immune interactions, organoids provide a faster, more scalable platform for studying cancer biology and drug responses. These models can be generated in a significantly shorter timeframe and are more amenable to high-throughput screening, facilitating the evaluation of therapeutic efficacy across a broad range of drug candidates. Recent advancements in organoid technology have led to the development of patient-derived tumor organoid (PDTO) biobanks, which serve as living, dynamic resources for studying the progression of cancer, metastasis, and the development of drug resistance. PDTOs have emerged as particularly useful in precision medicine, as they enable the identification of potential treatments tailored to the unique molecular and genetic profile of an individual's tumor.

Subculturing Protocol for the MDA-MB-453 Cell Line

At Altogen Labs, when subculturing MDA-MB-453 cells, we begin by using Corning T-75 flasks and adjusting the volumes of reagents proportionally for different culture vessel sizes. First, the culture medium is removed and discarded, and the cell layer is briefly rinsed with 0.25% (w/v) Trypsin-0.53 mM EDTA solution to remove serum traces that may contain trypsin inhibitors. We then add 2.0 to 3.0 mL of Trypsin-EDTA solution to the flask and carefully monitor the cells under an inverted microscope until the cell layer disperses, typically within 5 to 15 minutes. To avoid clumping, we ensure not to agitate or shake the flask; if needed, the flask is placed at 37°C to aid in the detachment process. Once the cells have detached, we add 6.0 to 8.0 mL of complete growth medium and gently pipette to aspirate the cells. The cell suspension is then aliquoted into new culture vessels and incubated at 37°C without CO_2. For optimal growth, we typically use a subcultivation ratio of 1:2 to 1:6 and renew the medium 2 to 3 times per week.

Altogen Labs offers a comprehensive range of laboratory services utilizing over 30 established Cell Line Derived Xenograft (CDX) models and more than 20 Patient-Derived Xenograft (PDX) models. These models enable researchers to investigate the role of specific proteins and gene products in tumor growth regulation. The laboratory specializes in generating genetically engineered cell lines with protein overexpression or RNA interference (RNAi)-mediated gene silencing, allowing for precise modulation of tumor suppressors and oncogenes. Additionally, Altogen Labs provides quantitative gene expression analysis via real-time PCR (RT-PCR) and protein expression analysis using the WES system by ProteinSimple, ensuring high-resolution detection.

Figure 4. Available Altogen Labs *in vivo* xenograft services for MDA-MB-453 (Altogen Labs).

Xenograft studies at Altogen Labs follow a structured approach, with compound dosing initiated once the mean tumor volume reaches a specified threshold (typically 90-100 mm³) in staged studies or immediately post-engraftment in unstaged studies. Mice are administered test compounds via various routes, including intravenous, intraperitoneal, oral gavage, and intratumoral injections; once or twice daily for 28 days or a customized study duration. The facility adheres to IACUC regulations and maintains GLP compliance, ensuring ethical and rigorous animal care. Additional services include histological analysis, gene expression profiling, blood chemistry assessments, toxicity and survival studies, and fluorescence-based imaging. Specialized protocols are available for the MDA-MB-453 xenograft model, including tumor growth inhibition (TGI), tumor growth delay (TGD), and metastasis studies using alternative engraftment sites.

Figure 5. *In vivo* toxicology services at Altogen Labs for MDA-MB-453 (Altogen Labs).

References:

Guerram M, Jiang ZZ, Yousef BA, Hamdi AM, Hassan HM, Yuan ZQ, Luo HW, Zhu X, Zhang LY. The potential utility of acetyltanshinone IIA in the treatment of HER2-overexpressed breast cancer: Induction of cancer cell death by targeting apoptotic and metabolic signaling pathways. *Oncotarget*. 2015 Sep 8;6(26):21865-77. doi: 10.18632/oncotarget.4156. PMID: 26068969; PMCID: PMC4673132.

Ichihara H, Okumura M, Tsujimura K, Matsumoto Y. Theranostics with Hybrid Liposomes in an Orthotopic Graft Model Mice of Breast Cancer. *Anticancer Res*. 2018 Oct;38(10):5645-5654. doi: 10.21873/anticanres.12900. PMID: 30275183.

Luo LP, Han B, Yu XP, Chen XY, Zhou J, Chen W, Zhu YF, Peng XL, Zou Q, Li SY. Anti-metastasis activity of black rice anthocyanins against breast cancer: analyses using an ErbB2 positive breast cancer cell line and tumoral xenograft model. *Asian Pac J Cancer Prev*. 2014;15(15):6219-25. doi: 10.7314/apjcp.2014.15.15.6219. PMID: 25124601.

Moore NL, Buchanan G, Harris JM, Selth LA, Bianco-Miotto T, Hanson AR, Birrell SN, Butler LM, Hickey TE, Tilley WD. An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. *Endocr Relat Cancer*. 2012 Jul 22;19(4):599-613. doi: 10.1530/ERC-12-0065. PMID: 22719059.
Vranic S, Gatalica Z, Wang ZY. Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies. *Oncol Lett*. 2011 Nov;2(6):1131-1137. doi: 10.3892/ol.2011.375. PMID: 22121396; PMCID: PMC3224077.

Keywords: MDA-MB-453, breast cancer, xenograft, breast, *in vivo*, cancer, preclinical, research, *in vivo* pharmacology, CDX, PDX, organoids, *in vivo* toxicology, orthotopic, metastatic